Primary Cardiovascular Prevention: 2019 ACC/AHA Guideline Update
Eighty percent of all cardiovascular events are preventable. The ACC/AHA 2019 guidelines are a single source of best practices to help achieve that goal. Review them here, at-a-glance.
In a commentary on the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, guideline co-chair Roger Blumenthal, MD and colleagues emphasize 3 “overarching central recommendations” that apply to all ASCVD prevention efforts: Adopting a team-based approach; engaging patients in shared decision making; and, addressing social determinants of health to inform optimal treatment. The guideline framework is simple but adherence to the recommendations can have far-reaching effects on US morbidity and mortality. Each of the slides below offers a snapshot of one key prevention principle. Â
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
